Drug Discovery@nature.com 21 February 2014

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS 21 February 2014 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Nature Medicine Focus on Targeted Cancer Therapies   In this special Focus, Nature Medicine is proud to present a collection of Reviews and a Perspective tackling some of the most exciting issues in translational cancer research, discussing recent advances and providing a view of what to expect in the near future.   Click here to access this Focus for free!   Sponsored by: Genentech    News Top Investor stampede for CARs doi:10.1038/nbt0214-112 Juno Therapeutics raised US$145 million in early-stage venture capital funding to develop a chimeric antigen receptor (CAR)-modified T-cell therapy for refractive B-cell malignancies. Full Text Setback for JAK2 inhibitors doi:10.1038/nbt0214-119a Sanofi has abandoned development of its JAK2 inhibitor fedratinib after a phase III trial for myelofibrosis was halted owing to signs that the drug might cause Wernicke's encephalopathy. Full Text Fresh from the biotech pipeline—2013 doi:10.1038/nbt.2811 Despite an overall dip in FDA approvals of new chemical and biologic entities, 2013 wasn't a bad year for innovator drugs. Jim Kling reports. Full Text With pot now legal, therapies sought to blunt high of marijuana doi:10.1038/nm0214-107 As marijuana consumption is legalized in an increasing number of US states, various pharmacotherapies that could ameliorate addiction to the drug are under investigation. Full Text Analysis Top Curb your fatty acids doi:10.1038/scibx.2014.159 A team has uncovered MFGE8 as a new obesity target and is working on inhibitors of the integrin ligand or its receptors for use in the indication. Full Text Biosimilar competition: lessons from Europe doi:10.1038/nrd4210 Grabowski and colleagues analyse the European market uptake of biosimilar versions of two major therapeutic biologics — epoetin alfa and filgrastim — and discuss the implications for the future development of the market for biosimilars. Full Text Research Highlights Top Kidney disease: Targeting a faulty filter doi:10.1038/nrd4234 ML204, a small-molecule inhibitor of transient receptor potential channel 5, protects against injury in a mouse model of kidney damage. Full Text Phenotypic screening: A more rapid route to target deconvolution doi:10.1038/nrd4243 Combining activity-based protein profiling with phenotypic screening to improve drug target identification. Full Text Neurodevelopmental disorders: The gut–microbiome–brain connection doi:10.1038/nrd4235 Targeting the gut microbiota could be useful for treating behavioural symptoms in autism spectrum disorder. Full Text Research & Reviews Top PI3K and cancer: lessons, challenges and opportunities doi:10.1038/nrd4204 Fruman and Rommel discuss the complexity of the phosphoinositide 3-kinase signalling network in cancer, address challenges associated with therapeutic intervention and propose strategies to guide future research efforts. Full Text Herpesvirus-encoded GPCRs: neglected players in inflammatory and proliferative diseases? doi:10.1038/nrd4189 The authors discuss how herpesvirus-encoded G protein-coupled receptors — which can hijack downstream signalling pathways in host cells — could be promising targets in certain inflammatory and proliferative diseases. Full Text The role of ligand efficiency metrics in drug discovery doi:10.1038/nrd4163 This article discusses how the application of ligand efficiency metrics (the molecular properties required to gain binding affinity for a drug target) has the potential to increase the quality of drug candidates. Full Text Inflammasomes in the CNS doi:10.1038/nrn3638 This Review describes our current understanding of the functions of different inflammasomes in the CNS and their roles in neurological diseases. Full Text Drug Discovery JOBS of the week Postdoc Cancer Biology for Drug Discovery Italian Institute of Technology (ITT) Tier 2 Canada Research Chair in Molecular Pharmacology and Drug Discovery University of Ottawa Tenure track, Assistant / Associate Professor position with expertise in Drug Discovery: Michigan State University Medicinal Chemistry Faculty Position University of Tennessee College of Pharmacy More Science jobs from Drug Discovery EVENT 17th International Conference on Drug-Drug Interactions 30.06.14 Seattle, USA More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.